CVM

CEL-SCI Corporation (CVM) - 10-K Summary

Business Context and Reporting Period

Company: CEL-SCI Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2025
Business Overview: CEL-SCI is a late clinical-stage biotechnology company focused on developing immunotherapies. Its lead candidate, Multikine, is an investigational Phase 3 therapy for head and neck cancer, administered locally before surgery. The company also develops the LEAPS technology platform for autoimmune diseases like rheumatoid arthritis. CEL-SCI has no approved products and generates no product revenue.

Key Financial Metrics

Note: The company raised approximately $28.3 million in gross proceeds from equity financings during fiscal 2025.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $1.5 million (5.6%) compared to 2024, primarily driven by a $2.1 million reduction in stock-based compensation expenses within R&D.
• Cash Position: Cash and cash equivalents increased by $6.2 million to $11.0 million, resulting from net proceeds from equity offerings ($25.0 million net) offset by operating cash outflows ($17.0 million) and lease payments.
• Stock Split: A 1-for-30 reverse stock split became effective on May 20, 2025. All share and per-share data in this report have been adjusted retroactively.
• Patent Impairment: The company abandoned five patents in 2025, resulting in an impairment charge of $18,275.

Guidance, Outlook, and Risks

Outlook and Strategy:

• Multikine Confirmatory Study: CEL-SCI plans to conduct a 212-patient confirmatory registration study for Multikine in the target population (low PD-L1 expression, no lymph node involvement). The estimated cost is approximately $30 million.
• Regulatory Pathway: The company seeks accelerated or conditional approval based on Phase 3 data showing a 73% 5-year survival rate vs. 45% for control. A Breakthrough Medicine Designation application was filed in Saudi Arabia in August 2025.
• Capital Needs: Management states the company requires substantial additional capital to fund the confirmatory study and operations. There is substantial doubt about the company's ability to continue as a going concern without raising additional funds.

Risks and Contingencies:

• Going Concern: Recurring losses and limited cash balances raise substantial doubt about the ability to continue operations for more than 12 months.
• Internal Controls: Management identified material weaknesses in internal control over financial reporting as of September 30, 2025, specifically regarding IT logical access and management review controls.
• Regulatory Approval: No assurance exists that Multikine will receive FDA approval or that the confirmatory study will be successful.
• Liquidity: Failure to raise capital could force the company to delay, limit, or terminate development efforts.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the $11.0 million cash balance against the estimated $30 million cost of the confirmatory study and ongoing operating burn rate.
• Capital Raising: Monitor upcoming equity offerings or partnership announcements required to fund the confirmatory study.
• Internal Controls: Review the remediation plan for the identified material weaknesses in internal controls over financial reporting.
• Regulatory Milestones: Track the initiation and enrollment progress of the 212-patient confirmatory registration study.
• Stock Dilution: Assess the impact of the 1-for-30 reverse split and potential future equity issuances on shareholder ownership.